A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

Trial Profile

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2013

At a glance

  • Drugs Liraglutide (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ADELANTE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 May 2012 Actual initiation date 23 Apr 2012 added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top